Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Conditions:   Lymphoma;   Lymphoma, Mantle-Cell;   Neoplasms by Histologic Type;   Neoplasms;   Lymphoproliferative Disorders Interventions:   Biological: IM19 CAR-T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine Sponsor:   Beijing Immunochina Medical Science& Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2021 Category: Research Source Type: clinical trials

Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors
Condition:   Liver Cancer Interventions:   Biological: IM83 CAR-T cells;   Combination Product: The second-line treatment of liver cancer Sponsor:   Beijing Immunochina Medical Science& Technology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2021 Category: Research Source Type: clinical trials